Gilead and arcus announce anti-tigit domvanalimab continues to demonstrate consistent improvement in progression-free survival in non-small cell lung cancer study

Foster city, calif., & hayward, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) and arcus biosciences, inc. (nyse: rcus) today announced updated results from an interim analysis of the arc-7 study in patients with first-line, metastatic non-small cell lung cancer (nsclc) with pd-l1 tumor proportion score (tps) ≥50% without epidermal growth factor receptor (egfr) or anaplastic lymphoma kinase (alk) mutations. arc-7 is the first phase 2, randomized, open-label study evaluating the c.
RCUS Ratings Summary
RCUS Quant Ranking